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Abstract 
Introduction:  Peripartum Cardiomyopathy (PPCM) is a rare, poorly understood disease process 
with significant clinical implications in pregnant women during and after delivery.  Improvement 
in left ventricular (LV) ejection fraction (EF) varies widely and few studies exist that define 
predictors of improvement in LV function in this sub population. The use of implantable 
cardioverter defibrillator (ICD) has also not been clearly understood in this population. 
Methods: A retrospective study was conducted at 2 academic centers between January 1
st
 1999 
and December 31
st
 2010.  Clinical and demographic variables and delivery records of patients 
with a discharge or outpatient diagnosis of PPCM (ICD9 -674.5) were reviewed. Patients were 
followed over time until December 31st 2012 to assess improvement in LV function. 
Results:  The total sample comprised 100 patients of whom 55% were African Americans, 39% 
were Caucasians and 6% were Hispanic with mean age of 30±6 years. The mean time to 
diagnosis after delivery was 1.1±4 weeks. Mean EF at diagnosis was 28±9%. Forty two percent 
of patients showed some improvement in LVEF over a mean duration of 33±21 months.  
Postpartum diagnosis (HR 3, p=0.01) and Caucasian/Hispanic race (HR 2.2, p=0.01) were 
predictors of LVEF improvement. Only 7 of the 58 patients (12%) who did not improve their EF, 
had ICD implanted. There were 11 deaths with a trend towards higher mortality in those that did 
not display improved LV function (15% vs. 5%, p=0.1).  
Conclusions: More than one-third of the women with PPCM improve LV function with delayed 
recovery noted in the majority of these women.  Caucasians and those diagnosed postpartum 
seem to be most likely to recover. ICDs were underutilized for primary prevention of sudden 
cardiac death in this population. 
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Introduction: 
          Peripartum cardiomyopathy (PPCM) is a rare, life threatening disease characterized by the 
development of heart failure in the last month of pregnancy or within 5 months of delivery (1, 2). 
The reported incidence shows significant geo-demographic variation from 1 in 500 live births in 
Haiti to 1 in 4000 live births in the USA (3 -6). Identified risk factors for PPCM include 
multiparity, advanced maternal age, twins, preeclampsia, gestational hypertension and African-
American race (7-10). 
          Despite the recognition of this disease as a separate entity in 1937 (1), the mortality rates 
are still not well characterized (8-19) ranging from 4 % to 50% (2, 8-19). At least a quarter of 
deaths in PPCM are caused by ventricular tachyarrhythmias (16). Sudden cardiac death in these 
young women could potentially be averted by implantation of a cardioverter-defibrillator (ICD) 
and cardiac resynchronization (CRT) devices may reduce progression to end stage myocardial 
dysfunction. ACC/AHA/ESC 2009 guidelines recommend implantation of an ICD for primary 
prevention of sudden cardiac death in all patients with EF≤ 35% (20).To date, there are no 
studies that report the use of ICD or CRTD for primary prevention in this population. PPCM is 
also reported to be associated with a higher likelihood of recovery of left ventricular (LV) 
function than cardiomyopathy from other causes (2,10,17,19,21). Thus, predicting who recovers 
from the disease helps determine who might best benefit from an ICD implantation. Previous 
studies have shown that baseline LV ejection fraction (EF) >30%, LVEDD < 5.5cm, older age 
and Caucasian race predicted recovery of LV function (22-29). However these are single center 
studies with small sample sizes of ≤ 55 patients or the information was obtained from other 
countries and surveys that are subject to ascertainment, recall and selection bias.   
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           We thus wanted to study the mortality and LV recovery rates and examine the ICD 
implantation rates at tertiary academic centers that offer a good mix of patients of different 
ethnicities. We sought to identify the predictors for LV recovery and the current rates of ICD 
use. 
Methods: 
          This is a retrospective study conducted at two large tertiary care academic centers, 
University of Kansas, Kansas City and Detroit Medical Center, Detroit where cardiovascular and 
high risk pregnancy services are available.  IRB approval was obtained from both institutions. 
Patients: All patients > 18 years of age who were diagnosed with postpartum/peripartum 
cardiomyopathy at the 2 centers were studied. The medical records of these patients were 
identified by using ICD-9 diagnostic codes for PPCM (674.50. 674.51, 674.52, 674.53, 674.54) 
that were used for discharge diagnoses from the hospital and/or ambulatory clinic visits. At 
University of Kansas, medical records were obtained for patients diagnosed between January 1
st
 
2004 and August 31
st
 2010. At the Detroit Medical Center, records were obtained for patients 
that were diagnosed with PPCM between January 1
st
 1999 and December 31
st
 2010. All delivery 
records and follow-up encounters were reviewed for clinical and demographic information. 
Patients with a history of prior cardiomyopathy from other causes or structural heart disease were 
excluded. Each patient was followed until December 2012 for any improvement in EF. The date 
of the last echo was considered as the last follow-up date for those without any improvement in 
EF. Time to recovery was noted for patients who had improvement in LV function. ICD 
implantation was also noted. All-cause mortality was obtained from the social security death 
index and confirmed by chart review when available. 
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Assessment of Ejection fraction (EF): EFs at the time of diagnosis of PPCM were recorded and 
termed as baseline EF. Each patient was followed over time to assess EF and the EF from the last 
echocardiogram report was noted for those without LV improvement. For patients who had an 
improvement in EF, the EF and the time to improvement in EF were noted. 
Definition of improvement: An EF > 50% at follow-up was considered as complete recovery. If 
the EF remained < 35%, it was considered as no improvement. If the follow-up EF was between 
35% and 50% the improvement was considered partial provided that there was > 10% positive 
change from baseline. 
If patients had either partial or complete improvement they were included in the ‘any’ 
improvement category used for the analysis. 
Statistical analysis: Statistical analysis of the data was performed using SAS version 9.3 (SAS 
Inc, North Carolina, USA).  Chi square was used for comparisons of categorical data and 
Student’s t-test for continuous parameters.  A Cox proportional hazards model was used to assess 
the predictors for any improvement in EF after adjusting for significant covariates. Univariate 
predictors were initially obtained and if p<0.1, they were included in the multivariate analysis. 
Baseline EF was tested both as a continuous variable as well as a categorical variable (EF < 30% 
and > 30%) to see if it predicted recovery or mortality. Statistical significance was considered 
present when p < 0.05 in the multivariate analysis. The model fit was tested using the test for 
proportionality.  Kaplan Meier curves for improvement in EF and mortality were constructed for 
the entire population. 
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Results:  
          The flowchart of cohort assembly is illustrated in figure 1. The final cohort consisted of 
100 patients with a mean age of 30±6.5 years. Mean duration of follow-up was 35±21 months.  
African-Americans predominated in the sample (55%) with 39% Caucasians and 6% Hispanics.   
 
Figure 1: Flow chart of patients  
 
Figure 2:  Time of Diagnosis (in weeks) of PPCM for each patient 
N=107 
•Initial cohort 
N=105 
•Excluded 2 patients with pre-existing cardiomyopathy 
N=100 
•Final cohort after excluding 5 patients with no follow-up data. 
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Maternal and Fetal Characteristics: Preeclampsia was diagnosed in 36%; 61% were 
multiparous. The majority of patients were diagnosed after delivery (71%). The mean time to 
diagnosis of PPCM was 1.1±4 weeks. Figure 2 shows the time to diagnosis for each patient. 
Forty patients had preterm delivery prior to 37 weeks and tocolytic agents were used in 9.  The 
cesarean section rate was 56%. Three women had stillbirths. The mean birth weight of the 
neonates was 3±0.92kg. Thirty five women had subsequent pregnancies. Mean NYHA class was 
2±1.2. Thirty percent (30%) of patients were in NYHA class 1, 15% in class II, 45% in class III 
and 8% in class IV. There were 4 patients with QRS duration > 120ms at baseline. Among 
patients who did not recover LV function, one woman had a ventricular assist device implanted. 
Two women were listed for heart transplantation. 
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Table1:  Baseline characteristics of all patients 
Variables 
Total 
(N=100) 
Improvement 
(N=42) 
No improvement 
(N=58) 
p 
value 
Age (years) 30±6.5 30±7 30±6.2 0.7 
Race (%) (African-American) 55 48 65 0.09 
Baseline EF (%) 28±9.9 29±9 28±10 0.9 
Diabetes (%) 29 23 32 0.3 
Hypertension(%) 33 35 31 0.8 
Gestational hypertension(%) 33 33 32 0.9 
Preeclampsia (%) 36 40 32 0.4 
Hyperlipidemia (%) 9 7 10 0.6 
Multiparity (%) 61 52 67 0.12 
Tobacco abuse (%) 30 39 24 0.12 
Alcohol (%) 11 14 8 0.3 
Cesarean section (%) 56 59 54 0.46 
Family history of cardiomyopathy(%) 13 14 12 0.7 
Left atrium enlarged (%) 64 64 63 0.9 
postpartum diagnosis (%) 71 83 62 0.02 
QRS duration (ms) 85±18 83±21 86±16 0.4 
Creatinine (mg/dl) 0.8±0.7 0.82±0.2 0.9±0.9 0.6 
Hemoglobin (mg/dl) 10.7±1.7 10.7±1.5 10.8±1.8 0.6 
Betablocker (%) 82 89 78 0.2 
ACEI/ARB (%) 85 83 86 0.7 
 
 
 
 
Table 2:  Distribution of baseline Ejection Fraction against follow-up Ejection Fraction 
Baseline 
Ejection 
Fraction 
Follow-
up EF 
<20% 
Follow-up 
EF  
20%-30% 
Follow-up 
EF  
31%-50% 
Follow-
up EF  
>50% 
Percent 
improved (per 
study definition) 
<20% n=8 n=2 n=2 n=1 n=3/13   (23%) 
20%-30% n=10 n=7 n=12 n=13 n=22/42 (52%) 
31%-50% n=7 n=13 n=16 n=9 n=17/45 (38%) 
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LV recovery:  Forty two of 100 patients (42%) had ‘any’ improvement in EF over a mean 
duration of 33±21 months.  Of these patients, 23 women had complete improvement while 19 
had partial recovery of LV function. Baseline characteristics of patients with and without 
improvement in EF are shown in table 1. The distribution of baseline EF versus follow-up EF is 
shown in table 2. The mean baseline EF was 28±9.9%.  The mean EF at follow-up for the entire 
group was 34±18% during a mean follow-up duration of 35±21 months. Figure 3 demonstrates 
the range of improvement in EF that occurred with different baseline EFs of < 20%, 20 to 30% 
and >30%.  
 
Figure 3: Box and Whisker plot of follow-up EF against baseline EF 
Table 3: Multivariate predictors of LV recovery 
Predictors Hazard 
Ratio 
95% Confidence 
interval 
p value 
Race (African-American vs 
other) 0.45 0.2-0.8 0.01 
Postpartum Diagnosis 3 1.2-7 0.01 
Diabetes 0.4 0.2-1 0.06 
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In women who had any improvement (partial and complete) in LV function, the mean baseline 
EF was 29±8% and the mean follow up EF was 52%±5%. The mean baseline EF in patients with 
complete recovery was 30 ±9% and the mean follow-up EF was 56% over a mean of 26 ±22 
months. Of these, only 4 women had complete improvement within 6 months. Delayed complete 
recovery beyond 6 months was noted in 83% (n=19/23) of patients.  The mean baseline EF in 
patients with partial improvement was 30±9% and the mean follow-up EF was 48% and was 
achieved after a mean of 40±17 months.  Univariate and multivariate analysis of predictors of 
LV recovery (any improvement) revealed that race (Caucasians and Hispanics) and postpartum 
diagnosis were the predictors of LV recovery while there was a trend for no improvement in LV 
function in patients with diabetes (See table 3). A Kaplan-Meier curve for recovery of LV 
function is shown in figure 4. 
Mortality: The majority of the women were treated with optimal therapy for heart failure (beta-
blockers and angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers 
(ARBs)). There was no difference in the use of beta-blockers and ACEI/ ARBs in patients with 
and without recovery of LV function (see table 1). Eleven women died (n=11) during an average 
follow-up of 29±29 months. Nine were in the group that did not recover. There was a trend 
towards higher mortality in the group that did not recover their LV function (15% vs 5%, 
p=0.09). Only 1 had an ICD and died from intractable heart failure.  Two other women died from 
arrhythmic causes while the cause of death is not known in 8 other patients. A Kaplan Meier 
survival curve for the entire group is shown in figure 5. 
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Figure 4: Kaplan-Meier curve showing proportion of patients not-improved over time. 
ICD use: Thirteen women (n=13) had ICDs implanted at some point including 2 with cardiac 
resynchronization therapy devices (CRTD). Six women among the 41 who had complete 
recovery of PPCM received an ICD early in their follow-up (n=6/42, 14%) while 7 (n=7/58, 
12%) patients without any EF improvement received ICDs. Fifty four of the 59 patients who did 
not recover had EF ≤35% and qualified for an ICD device for primary prevention of sudden 
cardiac death; only 7 (13%) had a device implanted. ICD implantation was for primary 
prevention in 12 patients and secondary prevention in 1 patient. 
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Figure 5: Kaplan –Meier survival curve for the entire population 
 
Discussion: 
          We found that a substantial proportion of patients with PPCM recover LV function (42%), 
complete recovery occurred in 23%. Our follow-up duration was long enough to note delayed 
complete recovery of EF beyond 6 months in majority of the patients in both Caucasians and 
African-Americans (83%). This study underlines the high mortality rate (11%) in these young 
women. This is the one of the first studies to address ICD use and suggests their underutilization 
according to guidelines.  
          PPCM is distinct from other types of heart failure, although the symptoms resemble that of 
dilated cardiomyopathies.  Oxidative stress, genetic susceptibility, auto-immunity and 
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myocarditis have all been implicated in the pathogenesis (2, 30). Complete recovery of 
ventricular function occurs in substantial proportion of women which is unusual in other forms 
of cardiomyopathy (6). Complete recovery was seen in 23% of patients in our study and partial 
recovery in 19%. Other studies have reported rates complete recovery rates between 20 and 60% 
(22-30). Factors predictive of recovery suggested in prior studies included baseline ejection 
fraction ≥30%, LV end diastolic diameter<5.5cm (22-26). All these studies were from single 
centers that involved less than 55 patients with limited follow- up and none of these studies were 
controlled for other covariates. The present study is one of the largest studies in the United States 
with clinical and echocardiographic variables that were included in the model unlike the study by 
Goland et al that primarily assessed echocardiographic predictors (26). A recent report of 176 
South African peripartum cardiomyopathy patients followed only for 6 months concluded that 
older age and lower LV end systolic diameter but not the EF, predicted recovery (27). However, 
this may not be applicable to our population given the racial and genetic differences. We did not 
find age to be a predictor, but did find confirm that race and postpartum diagnosis were 
predictors. The differences may also be explained by our longer follow-up duration as delayed 
recovery of EF beyond 6 months has been reported in 3 other recent studies. (18,31,32).  Biteker 
et al (31) noted that only 14% of Turkish women recovered their EF in the first 6 months while 
another 33% of women recovered beyond 6 months. Modi et al reported a median time to 
recovery of 54 months in African-American women in the United States (18) while Fett followed 
32 PPCM patients in Haiti and found that the mean duration to LV recovery was 35 months (32). 
This is important to note as some have concluded that EF recovery occurs in the first 6 months 
and persistence of LV dysfunction beyond 6 months is a marker of worse survival (2). In the 
present study, complete recovery of EF within 6 months was seen in only 4 patients (17%) while 
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delayed recovery occurred in 83% of patients. To our knowledge our study is the first to note 
delayed recovery of EF in Caucasian women with PPCM. The Kaplan-Meier curve in figure 4 
shows 10% non-recovery rates after 5 years. Long term follow-up of these patients is thus 
needed and serial clinical and echocardiographic assessments of LV function recovery should be 
made. 
          Predictors of LV recovery in our study were race and postpartum diagnosis as was 
previously suggested in other studies (23, 33). There are several possibilities why an antepartum 
diagnosis could represent a worse outcome.  Early presentation could represent more severe 
disease. Treatment with optimal heart failure medications is limited during pregnancy at a stage 
when therapy is needed the most. It is also possible that these women had subclinical PPCM with 
a prior pregnancy that remained undiagnosed and has now progressed to become clinically 
manifest in the ante-partum stage of the subsequent pregnancy. There was a trend for worse 
outcomes in patients with diabetes. This association was not reported earlier with PPCM but is 
true in case of structural heart disease.  Prior studies were small and few included clinical 
variables. With the rising incidence of diabetes in the young population, this association may 
have now become evident. 
          Therapy for heart failure consists of optimal medical management and ICD/CRTD for 
primary prevention of sudden cardiac death (20). More than 80% of the population in our study 
was on beta-blockers and ACEI/ARBs. Small studies that predated guideline driven heart failure 
therapy have reported higher mortality rates. Recent studies in the current era including the 
present study show better outcomes (10, 12, 22). Some new therapies currently under 
investigation are pentoxiphylline and bromocriptine (34, 35, 36). A very recent prospective study 
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evaluated treatment with bromocriptine and suggests potential benefit in the European 
population (36). Cardiac resynchronization therapy has also been shown to be effective in this 
population (37). 
          Device therapy for primary prevention of sudden cardiac death in PPCM patients is not 
specifically addressed in the 2008 device therapy guidelines (38). The present study suggests that 
devices are underutilized in this population. Another study reported that 7 of 182 patients with 
PPCM had ventricular arrhythmias and underwent ICD implantation in a tertiary hospital in 
California, 3 of the ICDs were CRTDs (39). Similarly 3 of 14 patients without improvement 
underwent ICD implantation in a recent prospective study in Europe (36). Reasons for 
underutilization of ICDs in the present study are not too clear but possible reasons include lack 
of specific guidelines on the use of ICDs in PPCM patients, socio-economic factors, patient 
compliance, access to long term follow-up care and possible follow-up by physicians other than 
cardiologists who are probably not very familiar with the device indications for primary 
prevention of sudden cardiac death. 
          The need and the optimal time for device implantation in women with PPCM is difficult to 
state since even though delayed EF recovery may occur, risk for sudden death prior to recovery 
remains a concern. Baseline EF was not shown to be a predictor of recovery of LV function in 
our study and a few others (4, 18). Although EF was a predictor of improvement in a study by 
Goland et al, they concluded that baseline EF would not be useful as a marker for early 
implantation of ICDs since it had limited sensitivity in predicting a lack of EF improvement (29). 
The largest epidemiological study to date of 680 PPCM patients in North Carolina reported a 
high mortality rate of 16% (40) in these young women. Sudden death due to ventricular 
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arrhythmias occurred in 38% of women while 46% died of progressive heart failure and 15% 
from unknown causes in a study describing complications of PPCM (39).We thus suggest that 
patients with PPCM should undergo ICD implantation if no improvement is detected within the 
first 3-6 months, especially in African- American patients who are diagnosed with the disease 
antepartum to prevent sudden cardiac death. Subcutaneous ICDs may have a role in this 
population with the added advantage of not having an endovascular system and the subsequent 
issues related to device extraction especially in those with clinical improvement where a 
continued indication for primary prevention ceases to exist (41, 42). 
Limitations: This is a retrospective study with a reasonable size. We reported all-cause mortality 
and complete data on causes of death was not available in all patients.  
Conclusions: 
           In our study 42% of the women with PPCM improved their LV function with delayed 
recovery (>6 months) noted in the majority.  Caucasians/Hispanics and those diagnosed 
postpartum seem to have the highest recovery rates. ICDs are underutilized for primary 
prevention of sudden cardiac death in this population. Future studies should address the 
application of ICD and CRT in these women. 
 
 
 
 
 
 
15 
 
References: 
1.  Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, Gunnar 
RM. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053-1061. 
2. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, Ansari A, 
Baughman KL. Peripartum cardiomyopathy: national heart, lung and blood institute and 
office of rare diseases (national institutes of health) workshop recommendations and 
review. JAMA 2000;283:1183-1188 
3. Mielniczuk LM, Williams K, Davis DR. Frequency of peripartum cardiomyopathy. Am j 
cardiol 2006;97:1765 
4. Fett JD, Carraway RD, Dowell DL, king ME, Pierre R. Peripartum cardiomyopathy in the 
Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol 2002;186:1005. 
5. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in 
Africa. Circulation 2005;112:3577. 
6.  Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the 
incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin 
Proc 2005;80:1602. 
7. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: 
United States, 1991–97. Paediatr Perinat Epidemiol 2008;15:A36–7. 
8. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. 
Am J Obstet Gynecol 1997;176:182 -8. 
9. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, 
Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with 
initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-1084. 
16 
 
10. Lampert MB, Lang RM. Peripartum Cardiomyopathy. Am Heart J 1995;130(4):860–70. 
11. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward 
VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 
1995;25:118-123 
12. Barr SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY . Incidence, 
mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 
2007;100:302–4. 
13. Cunningham FG, Pritchard JA, Hankins GD, Anderson PL, Lucas MJ, Armstrong KF. 
Peripartum heart failure: idiopathic cardiomyopathy or compounding cardiovascular 
events? Obstet Gynecol. 1986;67:157-168. 
14. Ventura SJ, Peters KD, Martin JA, Maurer JD. Births and deaths: United States, 1996. 
Mon Vital Stat Rep. 1997;46(1 suppl 2):1-40. 
15. Elkayam U, Tummala PP, Rao K, Akhter MW, Karaalp IS, Wani OR, Hameed A, 
Gviazda I, Shotan A. Maternal and fetal outcomes of subsequent pregnancies in women 
with peripartum cardiomyopathy. N Engl J Med 2001;344: 1567–71. 
16. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. 
Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 
prospectively studied patients. Eur Heart J 2006; 27:441-446. 
17.  Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, Gunnar 
RM. Peripartum cardiomyopathy: clinical, O’Connell JB hemodynamic, histologic and 
prognostic characteristics. J Am Coll Cardiol 1986;8:52-6 
17 
 
18. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients 
with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 
2009;201(2):171. 
19. Sutton MS, Cole P, Plappert M, Saltzman D, Goldhaber S. Effects of subsequent 
pregnancy on left ventricular function in peripartum cardiomyopathy. AmHeart J. 
1991;121:1776-1778 
20. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam 
MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused 
Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in 
Adults. A Report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines: Developed in Collaboration With the 
International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-
2016 
21. Chee KH. Favourable outcome after peripartum cardiomyopathy: a ten-year study on 
peripartum cardiomyopathy in a university hospital. Singapore Med J. 2013 Jan;54(1):28-
31 
22. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy 
with contemporary. Am Heart J. 2006;152(3):509-13 
23. Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left 
ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the 
internet. Int J Cardiol. 2012;154(1):27-31 
24. Duran N, Günes H, Duran I, Biteker M, Ozkan M. Predictors of prognosis in patients 
with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008;101(2):137-40. 
18 
 
25. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A. Pregnancy-
associated cardiomyopathy: clinical characteristics and a comparison between early and 
late presentation. Circulation. 2005;111(16):2050-5 
26. Chapa JB, Heiberger HB, Weinert L, Decara J, Lang RM, Hibbard JU. Prognostic value 
of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005;105(6):1303-
8. 
27. Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker-Kleiner D, Sliwa 
K. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. 
Heart. 2013;99(5):308-13. 
28. Horgan SJ, Margey R, Brennan DJ, O'Herlihy C, Mahon NG. Natural history, 
management, and outcomes of peripartum cardiomyopathy: an Irish single-center cohort 
study. J Matern Fetal Neonatal Med. 2013;26(2):161-5 
29. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, Khatri N, Elkayam U. 
Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a 
predictor of recovery or persistence of severe dysfunction in women in the United States 
with peripartum cardiomyopathy. J Card Fail. 2011;17(5):426-30. 
30. Sliwa K, Hilfiker-Kleiner D, Pieske B, Mebazaa A, Pieske B, Buchmann E, Regitz-
Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, Watkins H, Shah AJ, 
Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray JJ. Current state 
of knowledge on aetiology, diagnosis, management, and therapy of peripartum 
cardiomyopathy: a position statement from the Heart Failure Association of the European 
Society of Cardiology Working Group on Peripartum Cardiomyopathy. Eur J Heart Fail 
2010;12:767. 
19 
 
31. Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum 
cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart 
Fail. 2012;14(8):895-901 
32. Fett JD, Sannon H, Thélisma E, Sprunger T, Suresh V . Recovery from severe heart 
failure following peripartum cardiomyopathy. Int J Gynaecol Obstet. 2009;104(2):125-7 
33. Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of 
African-American women with peripartum cardiomyopathy in the United States. J Card 
Fail. 2013;19(4):214-8 
34. Sliwa K, Skudicky D, Candy G, Bergmann A, Hopley M, Sareli P. The addition of 
Pentoxiphylline to conventional therapy improves outcome in patients with peripartum 
cardiomyopathy. Eur J Heart Fail 2002;4: 305. 
35. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, 
Yamac H, Labidi S, Struman I, Hilfiker-Kleiner D. Evaluation of bromocriptine in the 
treatment of acute severe peripartum cardiomyopathy. A proof of concept pilot study. 
Circulation 2010;121:1465. 
36. Haghikia A, Podewski E, Libhaber E, Labidi S, Fischer D, Roentgen P, Tsikas D, Jordan 
J, Lichtinghagen R, von Kaisenberg CS, Struman I, Bovy N, Sliwa K, Bauersachs J, 
Hilfiker-Kleiner D. Phenotyping and outcome on contemporary management in a 
German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 
2013;108(4):366 
37. Mouquet F, Mostefa Kara M, Lamblin N, Coulon C, Langlois S, Marquie C, de Groote P. 
Unexpected and rapid recovery of left ventricular function in patients with peripartum 
20 
 
cardiomyopathy: impact of cardiac resynchronization therapy. Eur J Heart Fail. 
2012;14(5):526-9 
38. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, 
Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, 
Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 
Guidelines for device-based therapy of cardiac rhythm abnormalities. American College 
of Cardiology; American Heart Association Task Force on Practice Guidelines; American 
Association for Thoracic Surgery; Society of Thoracic Surgeons. Heart Rhythm. 
2008;5(6):e1-62 
39. Goland S, Modi K, Bitar F, Janmohamed M, Mirocha JM, Czer LS, Illum S, 
Hatamizadeh P, Elkayam U. Clinical profile and predictors of complications in 
peripartum cardiomyopathy. J Card Fail. 2009 Oct;15 (8):645-50. 
40. Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy: population-based birth 
prevalence and 7-year mortality. Obstet Gynecol. 2012;120(5):1013-9. 
41. Cappato R, Smith WM, Hood MA, Crozier IG, Jordaens L, Spitzer SG, Ardashev AV, 
Boersma L, Lupo P, Grace AA, Bardy GH. Subcutaneous chronic implantable 
defibrillation systems in humans. J Interv Card Electrophysiol. 2012 Sep;34(3):325-32 
42. de Bie MK, Thijssen J, van Rees JB, Putter H, van der Velde ET, Schalij MJ, van Erven 
L. Suitability for subcutaneous defibrillator implantation: results based on data from 
routine clinical practice. Heart. 2013;99(14):1018-23 
 
